Drug Trial Radar · NCT07047144
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Sep 15, 2025
Primary completion
Nov 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Scholar Rock, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion of the Investigator or a Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score \<55.
Conditions
- Spinal Muscular Atrophy
- SMA
- Spinal Muscular Atrophy Type 2
- Spinal Muscular Atrophy Type 3
- Neuromuscular Manifestations
- Anti-myostatin
Interventions
ApitegromabDrug
Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
NusinersenDrug
Nusinersen is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered intrathecally per the prescribing information.
RisdiplamDrug
Risdiplam is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered orally per the prescribing information.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the PK of apitegromab in subjects <2 years old with SMATime frame: 52 Weeks
- Evaluate the PD of apitegromab in subjects <2 years old with SMATime frame: 52 Weeks
- Evaluate the motor function outcomes (ie, efficacy) due to apitegromab treatmentTime frame: 48 Weeks
Locations
23 sites in 7 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
Children's Hospital of Orange County (CHOC)
Orange, California · Recruiting
Stanford Neuroscience Health Center (SNHC)
Palo Alto, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Children's Healthcare of Atlanta
Atlanta, Georgia · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Helen DeVos Children's Hospital at Spectrum Health
Grand Rapids, Michigan · Recruiting
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Neurology Rare Disease Center
Flower Mound, Texas · Recruiting
Cook Children's Medical Center
Fort Worth, Texas · Recruiting
Texas Children's Hospital (TCH)-Clinical Care Center (CCC)
Houston, Texas · Recruiting
UZ Leuven - Campus Gasthuisberg
Leuven, Belgium · Recruiting
CHR Citadelle
Liège, Belgium · Recruiting
UZ Gent
Ghent, East-Flanders, Belgium · Recruiting
Hopital Trousseau - I-Motion
Paris, France · Recruiting
Fondazione I.R.C.C.S. - Istituto Neurologico Carlo Besta
Milan, Italy · Recruiting
Centro Clinico NeMO Milano - Fondazione Serena Onlus
Milan, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy · Recruiting
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands · Recruiting
Hospital Sant Joan de Déu Barcelona
Barcelona, Spain · Recruiting
Hospital Universitari i Politecnico La Fecnic La Fe
Valencia, Spain · Recruiting
Leeds General Infirmary Children's Research Department
Leeds, West Yorkshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.